HUE066839T2 - Eljárások kardiovaszkuláris kockázat csökkentésére - Google Patents
Eljárások kardiovaszkuláris kockázat csökkentéséreInfo
- Publication number
- HUE066839T2 HUE066839T2 HUE15712241A HUE15712241A HUE066839T2 HU E066839 T2 HUE066839 T2 HU E066839T2 HU E15712241 A HUE15712241 A HU E15712241A HU E15712241 A HUE15712241 A HU E15712241A HU E066839 T2 HUE066839 T2 HU E066839T2
- Authority
- HU
- Hungary
- Prior art keywords
- procedures
- cardiovascular risk
- reduce cardiovascular
- reduce
- risk
- Prior art date
Links
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461954094P | 2014-03-17 | 2014-03-17 | |
| US201462025400P | 2014-07-16 | 2014-07-16 | |
| US201462043182P | 2014-08-28 | 2014-08-28 | |
| EP15305293 | 2015-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE066839T2 true HUE066839T2 (hu) | 2024-09-28 |
Family
ID=52648962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15712241A HUE066839T2 (hu) | 2014-03-17 | 2015-03-13 | Eljárások kardiovaszkuláris kockázat csökkentésére |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20150284473A1 (hu) |
| EP (2) | EP3119810B1 (hu) |
| JP (3) | JP2017509624A (hu) |
| KR (3) | KR20250006995A (hu) |
| CN (3) | CN114558129A (hu) |
| AU (3) | AU2015231713B2 (hu) |
| CA (1) | CA2942549A1 (hu) |
| EA (1) | EA039310B1 (hu) |
| ES (1) | ES2978990T3 (hu) |
| HU (1) | HUE066839T2 (hu) |
| IL (1) | IL304491A (hu) |
| MX (1) | MX380767B (hu) |
| PL (1) | PL3119810T3 (hu) |
| WO (1) | WO2015142668A1 (hu) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| PL3318255T3 (pl) | 2009-06-15 | 2021-09-06 | Amarin Pharmaceuticals Ireland Limited | Kompozycje i sposoby leczenia udaru u pacjenta z jednoczesną terapią statyną |
| ES2674600T3 (es) | 2011-01-28 | 2018-07-02 | Sanofi Biotechnology | Anticuerpos humanos contra PCSK9 para su uso en métodos de tratamiento de grupos de sujetos particulares |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2773111T3 (es) | 2011-09-16 | 2020-07-09 | Regeneron Pharma | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| MX2015016887A (es) | 2013-06-07 | 2016-07-26 | Regeneron Pharma | Metodos para inhibir la aterosclerosis mediante la administracion de un inhibidor de pcsk9. |
| EA201690889A1 (ru) | 2013-11-12 | 2016-11-30 | Санофи Байотекнолоджи | Режимы дозирования для применения ингибиторов pcsk9 |
| MX2017000527A (es) * | 2014-07-14 | 2017-08-10 | Amgen Inc | Formulaciones de anticuerpos cristalinos. |
| EP3753575A1 (en) * | 2014-07-16 | 2020-12-23 | Sanofi Biotechnology | Methods for treating high cardiovascular risk patients with hypercholesterolemia using inhibitors of pcsk9 |
| KR20240017117A (ko) | 2014-07-16 | 2024-02-06 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| US10472424B2 (en) | 2014-09-23 | 2019-11-12 | Pfizer Inc. | Treatment with anti-PCSK9 antibodies |
| KR20240172758A (ko) | 2015-08-18 | 2024-12-10 | 리제너론 파아마슈티컬스, 인크. | 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체 |
| JOP20190112A1 (ar) * | 2016-11-14 | 2019-05-14 | Amgen Inc | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي |
| US10337070B2 (en) * | 2017-01-12 | 2019-07-02 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| KR102401796B1 (ko) | 2017-04-13 | 2022-05-25 | 카딜라 핼쓰캐어 리미티드 | 신규의 펩타이드 기재 pcsk9 백신 |
| CA3092936A1 (en) * | 2018-03-06 | 2019-09-12 | Sanofi Biotechnology | Use of pcsk9 inhibitor for reducing cardiovascular risk |
| EP3817768A4 (en) * | 2018-07-02 | 2022-07-06 | Abcentra, LLC | COMPOSITIONS AND METHODS FOR REDUCING LIPOPROTEIN A FORMATION AND TREATMENT OF AORTIC SCLEROSIS AND AORTIC STENOSIS |
| JP2021534185A (ja) * | 2018-08-17 | 2021-12-09 | アマリン ファーマシューティカルズ アイルランド リミテッド | スタチン治療対象における末梢動脈血行再建の必要性を低減する方法 |
| AU2019349563B2 (en) | 2018-09-24 | 2023-06-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
| LT3911648T (lt) | 2019-01-18 | 2025-01-10 | Astrazeneca Ab | 6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-onas kaip pcsk9 inhibitorius ir jo naudojimo būdai |
| WO2021098720A1 (zh) * | 2019-11-18 | 2021-05-27 | 康融东方（广东）医药有限公司 | 抗pcsk9抗体及其应用 |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CN114848849B (zh) * | 2022-04-25 | 2023-11-17 | 南方科技大学 | Pcsk9蛋白抑制剂在治疗心血管疾病中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| ES2674600T3 (es) * | 2011-01-28 | 2018-07-02 | Sanofi Biotechnology | Anticuerpos humanos contra PCSK9 para su uso en métodos de tratamiento de grupos de sujetos particulares |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
-
2015
- 2015-03-13 KR KR1020247040556A patent/KR20250006995A/ko active Pending
- 2015-03-13 KR KR1020167028383A patent/KR20160132459A/ko not_active Ceased
- 2015-03-13 WO PCT/US2015/020564 patent/WO2015142668A1/en active Application Filing
- 2015-03-13 EP EP15712241.7A patent/EP3119810B1/en active Active
- 2015-03-13 EA EA201691847A patent/EA039310B1/ru unknown
- 2015-03-13 KR KR1020227039740A patent/KR20220157516A/ko not_active Ceased
- 2015-03-13 HU HUE15712241A patent/HUE066839T2/hu unknown
- 2015-03-13 CA CA2942549A patent/CA2942549A1/en active Pending
- 2015-03-13 PL PL15712241.7T patent/PL3119810T3/pl unknown
- 2015-03-13 MX MX2016011975A patent/MX380767B/es unknown
- 2015-03-13 AU AU2015231713A patent/AU2015231713B2/en active Active
- 2015-03-13 CN CN202210141133.5A patent/CN114558129A/zh active Pending
- 2015-03-13 CN CN202210141115.7A patent/CN114642661A/zh active Pending
- 2015-03-13 US US14/657,192 patent/US20150284473A1/en not_active Abandoned
- 2015-03-13 ES ES15712241T patent/ES2978990T3/es active Active
- 2015-03-13 JP JP2016556709A patent/JP2017509624A/ja active Pending
- 2015-03-13 CN CN201580024259.2A patent/CN106794244A/zh active Pending
- 2015-03-13 EP EP24160083.2A patent/EP4403213A3/en active Pending
-
2021
- 2021-02-19 AU AU2021201118A patent/AU2021201118A1/en not_active Abandoned
- 2021-10-19 US US17/504,921 patent/US20220144969A1/en not_active Abandoned
-
2022
- 2022-07-22 JP JP2022116854A patent/JP2022141868A/ja active Pending
-
2023
- 2023-07-16 IL IL304491A patent/IL304491A/en unknown
-
2024
- 2024-07-19 JP JP2024115429A patent/JP2024147744A/ja active Pending
- 2024-07-31 AU AU2024205254A patent/AU2024205254A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024147744A (ja) | 2024-10-16 |
| EP3119810C0 (en) | 2024-02-28 |
| AU2015231713B2 (en) | 2020-11-19 |
| AU2024205254A1 (en) | 2024-10-03 |
| AU2021201118A1 (en) | 2021-03-11 |
| AU2015231713A1 (en) | 2016-10-20 |
| KR20160132459A (ko) | 2016-11-18 |
| PL3119810T3 (pl) | 2024-07-15 |
| EA201691847A1 (ru) | 2017-01-30 |
| EP3119810A1 (en) | 2017-01-25 |
| EA039310B1 (ru) | 2022-01-12 |
| CA2942549A1 (en) | 2015-09-24 |
| JP2017509624A (ja) | 2017-04-06 |
| JP2022141868A (ja) | 2022-09-29 |
| US20220144969A1 (en) | 2022-05-12 |
| MX2016011975A (es) | 2016-12-05 |
| WO2015142668A1 (en) | 2015-09-24 |
| EP3119810B1 (en) | 2024-02-28 |
| KR20220157516A (ko) | 2022-11-29 |
| ES2978990T3 (es) | 2024-09-23 |
| CN114558129A (zh) | 2022-05-31 |
| MX380767B (es) | 2025-03-12 |
| IL304491A (en) | 2023-09-01 |
| EP4403213A2 (en) | 2024-07-24 |
| US20150284473A1 (en) | 2015-10-08 |
| CN114642661A (zh) | 2022-06-21 |
| CN106794244A (zh) | 2017-05-31 |
| KR20250006995A (ko) | 2025-01-13 |
| EP4403213A3 (en) | 2024-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE066839T2 (hu) | Eljárások kardiovaszkuláris kockázat csökkentésére | |
| DK3134402T3 (da) | 4-amino-imidazoquinolinforbindelser | |
| DK3094728T3 (da) | Kiralt design | |
| DK3211743T3 (da) | Ø-til-netværk-omskiftningsfremgangsmåde | |
| DK3006072T3 (da) | Karadgang | |
| DK3222714T3 (da) | Phytasemutanter | |
| DK3119396T3 (da) | Muscarinreceptoragonister | |
| EP3230438C0 (en) | N-GLYCOSYLATION | |
| DE112015001664A5 (de) | Betätigungsaktuator | |
| DK3183340T3 (da) | Termolabile exonukleaser | |
| DK3154689T3 (da) | Komplekser | |
| DK3110439T3 (da) | Pcsk9-vacciner | |
| DE112015005041A5 (de) | Gargerätevorrichtung | |
| DK3154945T3 (da) | Komplekser | |
| DE102014000623A8 (de) | Halbhohlnietelement | |
| HUE047581T2 (hu) | Készítmény | |
| DK3009858T3 (da) | Skyradar | |
| DE112015002702T8 (de) | Turbolader | |
| DE112015001633A5 (de) | Betätigungsaktuator | |
| DK3447493T3 (da) | Proteinrettede ortologer | |
| ES1133830Y (es) | Columbario | |
| DK3091875T3 (da) | Vipbar taburet | |
| DE202014005655U8 (de) | llluminationsvorrichtung | |
| TH1501006654A (th) | วิธีการเชื่อมติดชิ้นส่วน | |
| DE112015005055A5 (de) | Gargerätevorrichtung |